NCT07281079 NNZ-2591 Phelan-McDermid Syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Move from a broad disease map to a decision-ready trial dossier. This focused report examines NCT07281079—A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome—using PatSnap Clinical Trials, Drug & Asset, and Company & Deal Intelligence MCP evidence. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.
MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.
Why NCT07281079 is a hot trial to watch
Phelan-McDermid Syndrome is no longer one homogeneous development market. The most consequential programs increasingly compete through a specific mechanism, biomarker, treatment line, delivery strategy or endpoint architecture. NCT07281079 is notable because it tests NNZ-2591 in a Phase 3 design with Efficacy of NNZ-2591 compared with placebo as measured by the Phelan-McDermid Syndrome Assessment of Change (PMSA-C) overall score. as a primary decision variable. The wider PatSnap topic query returned 9 trial records and 5 result records, so differentiation depends on evidence quality rather than activity alone.
PatSnap Clinical Trials MCP makes the protocol fields machine-readable, while the companion asset and organization servers add mechanism and sponsor context.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07281079 |
| Official title | A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome |
| Phase / status | Phase 3 / Recruiting |
| Intervention | NNZ-2591 |
| Sponsor | Neuren Pharmaceuticals Ltd. |
| Geography | Canada, United States |
| Enrollment | 160 |
| Primary endpoint | Efficacy of NNZ-2591 compared with placebo as measured by the Phelan-McDermid Syndrome Assessment of Change (PMSA-C) overall score. |
| Endpoint time frame | Week 13 |
| Primary completion | 2027-10-31 |
| Study completion | 2027-11-15 |
Design and endpoint interpretation
The design should be read as an evidence architecture, not just a phase label. The primary endpoint—Efficacy of NNZ-2591 compared with placebo as measured by the Phelan-McDermid Syndrome Assessment of Change (PMSA-C) overall score.—determines what uncertainty this study can resolve. The reported time frame is Week 13. Enrollment of 160 participants and geography in Canada, United States shape statistical precision, operational risk and external validity. A strong readout will need to be interpreted against baseline risk, prior treatment, assessment schedule, missing-data handling and the clinical relevance of the observed effect.
Benchmark readouts in the same clinical field
- NNZ-2591 in Children and Adolescents With Phelan-McDermid Syndrome (Phase 2): TEAE = NNZ-2591 was well tolerated; most treatment-emergent adverse events were mild to moderate .
- An Open Label Trial of Growth Hormone in Children and Adolescents With Phelan-McDermid Syndrome Targeting Social Withdrawal (Phase 2): Irritability baseline(Mean) = 10.31 score on a scale (Standard Deviation, 7.6); -; -.
- Neuren Phase 2 trial shows significant improvements in Phelan-McDermid syndrome (Phase 2): TESAE(gastroenteritis) = 1 pts .
These result records are contextual benchmarks rather than direct head-to-head evidence. Cross-trial comparisons can be distorted by population, line of therapy, endpoint definition, follow-up and analysis set. Their value is to clarify what magnitude and type of evidence the market already recognizes.
Build a living trial monitor: connect to PatSnap MCP Servers and track protocol changes, primary-completion dates and newly indexed results without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset context: NNZ-2591 (Phase 3; IGF-1).
Company & Deal Intelligence context: Neuren Pharmaceuticals Ltd. (NEU) — http://www.neurenpharma.com.
The sponsor profile matters because a trial's strategic value depends on more than scientific rationale. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes that connect biological activity with function, symptoms, survival or treatment burden.
- Sequencing evidence: randomized data after the most relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world care settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety monitoring or durability.
What to monitor next
Monitor recruitment status, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. The most important inflection point is not always the headline data release; a change in endpoint, population or ownership can alter probability of success months earlier.
Bottom line
NCT07281079 is a focused lens on Phelan-McDermid Syndrome development. Its value will be determined by whether NNZ-2591 can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from topic-level benchmark readouts.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
